BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7481870)

  • 1. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
    Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
    van Warmerdam LJ; Huizing MT; Giaccone G; Postmus PE; ten Bokkel Huinink WW; van Zandwijk N; Koolen MG; Helmerhorst TJ; van der Vijgh WJ; Veenhof CH; Beijnen JH
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
    Calvert AH
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-85-S2-90. PubMed ID: 9045345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.
    Calvert AH; Ghokul S; Al-Azraqi A; Wright J; Lind M; Bailey N; Highley M; Siddiqui N; Lunec J; Sinha D; Boddy A; Roberts T; Fenwick J
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):90-4. PubMed ID: 10190788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of paclitaxel and carboplatin in combination.
    Kearns CM; Belani CP; Erkmen K; Zuhowski M; Hiponia D; Zacharski D; Engstrom C; Ramanathan R; Trenn MR; Aisner J
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PubMed ID: 7481850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
    ten Bokkel Huinink W; Veenhof C; Huizing M; Rodenhuis S; Helmerhorst T; Dubbelman R; Dalesio O; Beijnen J; Winograd B
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-31-S2-33. PubMed ID: 9045333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
    Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):34-8. PubMed ID: 7939761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
    Giaccone G; Huizing M; Postmus PE; ten Bokkel Huinink WW; Koolen M; van Zandwijk N; Vermorken JB; Beijnen JH; Dalesio O; Pinedo HM
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):78-82. PubMed ID: 7544030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.